Annual Accounts Receivable
$3.99 M
-$820.00 K-17.05%
01 July 2024
Summary:
Enzo Biochem annual accounts receivable is currently $3.99 million, with the most recent change of -$820.00 thousand (-17.05%) on 01 July 2024. During the last 3 years, it has fallen by -$6.21 million (-60.89%). ENZ annual accounts receivable is now -83.76% below its all-time high of $24.56 million, reached on 31 July 2001.ENZ Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$3.99 M
+$53.00 K+1.35%
01 July 2024
Summary:
Enzo Biochem quarterly accounts receivable is currently $3.99 million, with the most recent change of +$53.00 thousand (+1.35%) on 01 July 2024. Over the past year, it has dropped by -$193.00 thousand (-4.62%). ENZ quarterly accounts receivable is now -84.36% below its all-time high of $25.49 million, reached on 30 April 2002.ENZ Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENZ Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -17.1% | -4.6% |
| 3 y3 years | -60.9% | -64.8% |
| 5 y5 years | -62.9% | -59.6% |
ENZ Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -60.9% | at low | -74.0% | +1.4% |
| 5 y | 5 years | -62.9% | at low | -74.0% | +1.4% |
| alltime | all time | -83.8% | at low | -84.4% | +1.4% |
Enzo Biochem Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| July 2024 | $3.99 M(-17.1%) | $3.99 M(+1.3%) |
| Apr 2024 | - | $3.94 M(-23.1%) |
| Jan 2024 | - | $5.12 M(+22.4%) |
| Oct 2023 | - | $4.18 M(-13.0%) |
| July 2023 | $4.81 M(+1.0%) | $4.81 M(-50.1%) |
| Apr 2023 | - | $9.64 M(-11.3%) |
| Jan 2023 | - | $10.87 M(-5.6%) |
| Oct 2022 | - | $11.52 M(+141.8%) |
| July 2022 | $4.76 M(-53.3%) | $4.76 M(-59.5%) |
| Apr 2022 | - | $11.76 M(-23.2%) |
| Jan 2022 | - | $15.32 M(+35.2%) |
| Oct 2021 | - | $11.33 M(+11.1%) |
| July 2021 | $10.20 M(+11.6%) | $10.20 M(-11.1%) |
| Apr 2021 | - | $11.47 M(-5.1%) |
| Jan 2021 | - | $12.10 M(+0.4%) |
| Oct 2020 | - | $12.05 M(+31.8%) |
| July 2020 | $9.14 M(-14.9%) | $9.14 M(+34.1%) |
| Apr 2020 | - | $6.82 M(-23.5%) |
| Jan 2020 | - | $8.91 M(-9.8%) |
| Oct 2019 | - | $9.88 M(-8.0%) |
| July 2019 | $10.74 M(-18.3%) | $10.74 M(-6.1%) |
| Apr 2019 | - | $11.44 M(-1.9%) |
| Jan 2019 | - | $11.66 M(-9.1%) |
| Oct 2018 | - | $12.84 M(-2.4%) |
| July 2018 | $13.15 M(-13.4%) | $13.15 M(-8.7%) |
| Apr 2018 | - | $14.41 M(-3.8%) |
| Jan 2018 | - | $14.98 M(+3.7%) |
| Oct 2017 | - | $14.44 M(-4.9%) |
| July 2017 | $15.18 M(+4.0%) | $15.18 M(-4.0%) |
| Apr 2017 | - | $15.80 M(+2.9%) |
| Jan 2017 | - | $15.36 M(+9.2%) |
| Oct 2016 | - | $14.06 M(-3.7%) |
| July 2016 | $14.59 M(+20.5%) | $14.59 M(+4.2%) |
| Apr 2016 | - | $14.00 M(+8.7%) |
| Jan 2016 | - | $12.88 M(+0.9%) |
| Oct 2015 | - | $12.76 M(+5.4%) |
| July 2015 | $12.11 M(-2.9%) | $12.11 M(+4.3%) |
| Apr 2015 | - | $11.61 M(-1.5%) |
| Jan 2015 | - | $11.79 M(-4.7%) |
| Oct 2014 | - | $12.38 M(-0.7%) |
| July 2014 | $12.47 M(+1.5%) | $12.47 M(+1.3%) |
| Apr 2014 | - | $12.31 M(+3.9%) |
| Jan 2014 | - | $11.86 M(-13.6%) |
| Oct 2013 | - | $13.72 M(+11.6%) |
| July 2013 | $12.29 M(-13.1%) | $12.29 M(-6.8%) |
| Apr 2013 | - | $13.19 M(+4.8%) |
| Jan 2013 | - | $12.58 M(-10.2%) |
| Oct 2012 | - | $14.00 M(-0.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| July 2012 | $14.13 M(-7.3%) | $14.13 M(+1.8%) |
| Apr 2012 | - | $13.89 M(+3.6%) |
| Jan 2012 | - | $13.40 M(-8.6%) |
| Oct 2011 | - | $14.67 M(-3.8%) |
| July 2011 | $15.24 M(+17.2%) | $15.24 M(+10.7%) |
| Apr 2011 | - | $13.77 M(+9.7%) |
| Jan 2011 | - | $12.55 M(-15.7%) |
| Oct 2010 | - | $14.88 M(+14.4%) |
| July 2010 | $13.01 M(+4.2%) | $13.01 M(+8.0%) |
| Apr 2010 | - | $12.04 M(+0.3%) |
| Jan 2010 | - | $12.01 M(-12.4%) |
| Oct 2009 | - | $13.70 M(+9.8%) |
| July 2009 | $12.48 M(-18.7%) | $12.48 M(+1.0%) |
| Apr 2009 | - | $12.36 M(+11.8%) |
| Jan 2009 | - | $11.05 M(-12.9%) |
| Oct 2008 | - | $12.69 M(-17.3%) |
| July 2008 | $15.35 M(+6.9%) | $15.35 M(+8.7%) |
| Apr 2008 | - | $14.12 M(+4.7%) |
| Jan 2008 | - | $13.49 M(-7.2%) |
| Oct 2007 | - | $14.53 M(+1.3%) |
| July 2007 | $14.35 M(+37.4%) | $14.35 M(+21.9%) |
| Apr 2007 | - | $11.78 M(+14.9%) |
| Jan 2007 | - | $10.25 M(+1.6%) |
| Oct 2006 | - | $10.09 M(-3.4%) |
| July 2006 | $10.45 M(-22.2%) | $10.45 M(-6.5%) |
| Apr 2006 | - | $11.18 M(-4.1%) |
| Jan 2006 | - | $11.65 M(-3.8%) |
| Oct 2005 | - | $12.11 M(-9.7%) |
| July 2005 | $13.42 M(-9.3%) | $13.42 M(-4.8%) |
| Apr 2005 | - | $14.10 M(-4.0%) |
| Jan 2005 | - | $14.68 M(+5.0%) |
| Oct 2004 | - | $13.98 M(-5.5%) |
| July 2004 | $14.79 M(-14.3%) | $14.79 M(-13.9%) |
| Apr 2004 | - | $17.19 M(+0.7%) |
| Jan 2004 | - | $17.07 M(+2.6%) |
| Oct 2003 | - | $16.64 M(-3.6%) |
| July 2003 | $17.27 M(-14.8%) | $17.27 M(-3.5%) |
| Apr 2003 | - | $17.89 M(-11.1%) |
| Jan 2003 | - | $20.11 M(-4.4%) |
| Oct 2002 | - | $21.05 M(+3.9%) |
| July 2002 | $20.27 M(-17.5%) | $20.27 M(-20.5%) |
| Apr 2002 | - | $25.49 M(+7.8%) |
| Jan 2002 | - | $23.65 M(-2.0%) |
| Oct 2001 | - | $24.14 M(-1.7%) |
| July 2001 | $24.56 M(+21.5%) | $24.56 M(+7.8%) |
| Apr 2001 | - | $22.78 M(+9.5%) |
| Jan 2001 | - | $20.81 M(+3.0%) |
| July 2000 | $20.21 M | $20.21 M |
FAQ
- What is Enzo Biochem annual accounts receivable?
- What is the all time high annual accounts receivable for Enzo Biochem?
- What is Enzo Biochem annual accounts receivable year-on-year change?
- What is Enzo Biochem quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Enzo Biochem?
- What is Enzo Biochem quarterly accounts receivable year-on-year change?
What is Enzo Biochem annual accounts receivable?
The current annual accounts receivable of ENZ is $3.99 M
What is the all time high annual accounts receivable for Enzo Biochem?
Enzo Biochem all-time high annual accounts receivable is $24.56 M
What is Enzo Biochem annual accounts receivable year-on-year change?
Over the past year, ENZ annual accounts receivable has changed by -$820.00 K (-17.05%)
What is Enzo Biochem quarterly accounts receivable?
The current quarterly accounts receivable of ENZ is $3.99 M
What is the all time high quarterly accounts receivable for Enzo Biochem?
Enzo Biochem all-time high quarterly accounts receivable is $25.49 M
What is Enzo Biochem quarterly accounts receivable year-on-year change?
Over the past year, ENZ quarterly accounts receivable has changed by -$193.00 K (-4.62%)